Zopiclone - Is it a phormacologic agent for abuse?

被引:0
|
作者
Cimolai, Nevio [1 ]
机构
[1] Childrens & Womens Hlth Ctr British Columbia, Dept Pathol & Lab Med, Vancouver, BC V6H 3V4, Canada
关键词
D O I
暂无
中图分类号
R1 [预防医学、卫生学];
学科分类号
1004 ; 120402 ;
摘要
OBJECTIVE To determine whether the hypnosedative drug zopiclone could be an agent for abuse. SOURCES OF INFORMATION Using MEDLINE and PubMed, English-language medical literature was systematically reviewed for reports of direct drug abuse and addiction. A review was also conducted for clinical trials or patient series that discussed issues of addiction or rebound effects. MAIN MESSAGE Evidence of drug abuse and dependency was found in case reports and small patient series. Dependency symptoms of severe rebound, severe anxiety, tremor, palpitations, tachycardia, and seizures were observed in some patients after withdrawal. Abuse occurred more commonly among patients with previous drug abuse or psychiatric illnesses. Many clinical trials have found evidence of rebound insomnia after recommended dosages were stopped, albeit for a minority of patients. Comparative studies of zopiclone and benzodiazepines or other "Z" drugs are conflicting. CONCLUSION Zopiclone has the potential for being an agent of abuse and addiction. While many have suggested that the addictive potential for this and other "Z" drugs is less than for most benzodiazepines, caution should be taken when prescribing this agent for insomnia. ideally, prescriptions should be given for a short period of time and within the recommended dosage guidelines.
引用
收藏
页码:2124 / 2129
页数:6
相关论文
共 50 条
  • [21] IMOVANE (ZOPICLONE)
    ANDERSON, A
    [J]. NEW ZEALAND MEDICAL JOURNAL, 1989, 102 (881) : 647 - 647
  • [22] Abuse and dependence potential for the non-benzodiazepine hypnotics zolpidem and zopiclone:: a review of case reports and epidemiological data
    Hajak, G
    Müller, WE
    Wittchen, HU
    Pittrow, D
    Kirch, W
    [J]. ADDICTION, 2003, 98 (10) : 1371 - 1378
  • [23] Pharmacokinetics of (S)-zopiclone and (S)-desmethylzopiclone following dosing with zopiclone and eszopiclone
    Brunello, N.
    Bettica, P.
    Amato, D.
    Maier, G.
    Nutt, D.
    [J]. EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2008, 18 : S581 - S582
  • [24] ABUSE OF AN ANTIHYPOTENSIVE AGENT EXPERIENCES WITH METAMFEPYRAMONE DEPENDENCE
    KEUP, W
    KELLERMANN, B
    WEIDIG, W
    [J]. MUNCHENER MEDIZINISCHE WOCHENSCHRIFT, 1986, 128 (43): : 733 - 734
  • [25] ELECTROANALYTICAL BEHAVIOR OF ZOPICLONE
    ZHANG, H
    VIRE, JC
    PATRIARCHE, GJ
    CHRISTIAN, GD
    [J]. ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 1990, 200 : 126 - ANYL
  • [26] BRAIN RECEPTORS AND ZOPICLONE
    BLANCHARD, JC
    BOIREAU, A
    JULOU, L
    [J]. PHARMACOLOGY, 1983, 27 : 59 - 69
  • [27] NEW HYPNOTICS - ZOPICLONE
    AYD, FJ
    [J]. PSYCHIATRIC ANNALS, 1984, 14 (08) : 618 - 619
  • [28] Electrochemical oxidation of zopiclone
    Jakub Táborský
    Martin Švidrnoch
    Ondřej Kurka
    Lucie Borovcová
    Petr Bednář
    Petr Barták
    Jana Skopalová
    [J]. Monatshefte für Chemie - Chemical Monthly, 2016, 147 : 53 - 60
  • [29] Clinical pharmacokinetics of zopiclone
    Fernandez, C
    Martin, C
    Gimenez, F
    Farinotti, R
    [J]. CLINICAL PHARMACOKINETICS, 1995, 29 (06) : 431 - 441
  • [30] Structural transformations in zopiclone
    Shankland, N
    David, WIF
    Shankland, K
    Kennedy, AR
    Frampton, CS
    Florence, AJ
    [J]. CHEMICAL COMMUNICATIONS, 2001, (21) : 2204 - 2205